Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457392 · ClinicalTrials.gov registry record · Phase 3
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 960
- Enrollment target
- 20
- Study locations
NCT00457392 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 960 participants, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (204% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00457392, a Phase 3 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 960 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
Conditions Studied
Interventions
- DRUG placebo
- DRUG sunitinib
- DRUG erlotinib
Study Locations (20)
California
- Pfizer Investigational Site - Antioch
- Pfizer Investigational Site - Burbank
- Pfizer Investigational Site - Downey
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - Montebello
- Pfizer Investigational Site - Pleasant Hill
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Leandro
- Pfizer Investigational Site - Whittier
Florida
- Pfizer Investigational Site - Brooksville
- Pfizer Investigational Site - Cocoa Beach
- Pfizer Investigational Site - Fort Lauderdale
- Pfizer Investigational Site - Merritt Island
Alabama
- Pfizer Investigational Site - Florence
- Pfizer Investigational Site - Muscle Shoals
Arizona
- Pfizer Investigational Site - Scottsdale
Arkansas
- Pfizer Investigational Site - Hot Springs
Connecticut
- Pfizer Investigational Site - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457392
The ClinicalTrials.gov registry entry for NCT00457392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (204% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00457392 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00457392 about?
NCT00457392 is a clinical study titled "A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone". This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
What is the current status of trial NCT00457392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2007-07. Estimated completion is 2012-12.
What conditions does trial NCT00457392 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00457392?
The interventions under investigation include: placebo (DRUG), sunitinib (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT00457392?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00457392 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.